Results 71 to 80 of about 2,000 (177)

Cost thresholds for anticipated long‐acting HIV pre‐exposure prophylaxis products in Eastern and Southern Africa: a mathematical modelling study

Journal of the International AIDS Society
Introduction Affordable HIV prevention tools are needed in Eastern and Southern Africa (ESA). Several promising long‐acting pre‐exposure prophylaxis (LA‐PrEP) products are available or in development. However, ESA settings face severe healthcare resource
David Kaftan, Monisha Sharma, Danielle Resar, Masabho Milali, Edinah Mudimu, Linxuan Wu, Cory Arrouzet, Ingrida Platais, Hae‐Young Kim, Sarah Jenkins, Anna Bershteyn   +10 more
doaj   +1 more source

Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee

Transfusion, EarlyView.
Nabiha H. Saifee, Jennifer Andrews, Mary Berg, Stella T. Chou, Mischa Covington, Elizabeth P. Crowe, Ruchika Goel, Juliana A. Guarente, Tina Ipe, Jeremy W. Jacobs, Jessica Jacobson, Cyril Jacquot, Jenna Khan, Thane A. Kubik, Theodros Mamo, Michael F. Murphy, Kerry O'Brien, Monica B. Pagano, Anil K. Panigrahi, Jacqueline N. Poston, Scott E. Potter, Simon J. Stanworth, Moritz Stolla, Alyssa Ziman, Ryan A. Metcalf   +24 more
wiley   +1 more source

Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered

AIDS (London)
Objective: To assess efficacy, safety and pharmacokinetics (PK) of oral lenacapavir (LEN) when used as oral bridging (OB) between delayed subcutaneous (SC) LEN injections. Design: Post-hoc analysis of participants in two clinical trials of SC LEN for HIV-
O. Ogbuagu, A. Avihingsanon, Sorana Segal-Maurer, Hui Wang, V. Jogiraju, Renu Singh, Martin S Rhee, H. Dvory‐Sobol, Peter Sklar, Jean-Michel Molina   +9 more
semanticscholar   +1 more source

Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure

eLife
The HIV-1 capsid has emerged as a tractable target for antiretroviral therapy. Lenacapavir, developed by Gilead Sciences, is the first capsid-targeting drug approved for medical use.
KM Rifat Faysal, James C Walsh, Nadine Renner, Chantal L Márquez, Vaibhav B Shah, Andrew J Tuckwell, Michelle P Christie, Michael W Parker, Stuart G Turville, Greg J Towers, Leo C James, David A Jacques, Till Böcking   +12 more
doaj   +1 more source

Mechanistic insights into lenacapavir-induced off-pathway HIV-1 capsid assembly

bioRxiv
The HIV-1 capsid is a fullerene-like shell composed of hexamer and pentamer arrangements of the capsid (CA) proteins. The cone shape of the capsid is particularly important for packaging the viral genome and coordinating nuclear entry. Lenacapavir (LEN),
Manish Gupta, Curt Waltmann, Nadine Renner, Yihang Wang, Leo C. James, D. Jacques, T. Boecking, Gregory A. Voth   +7 more
semanticscholar   +1 more source

A Systematic Review of Barriers and Facilitators to Long-Acting HIV Pre-Exposure Prophylaxis Uptake among Key Populations in Nigeria: Implications for Lenacapavir.

Panorama of Emergency Medicine
Background: Long-acting injectable pre-exposure prophylaxis (LAI-PrEP) offers a promising strategy for HIV prevention by addressing adherence challenges associated with daily oral pre-exposure prophylaxis (PrEP).
Adeyemi Ogedengbe Omoge, Modupe Oluwatimileyin Omoge, Oluwabunmi Bridget Erinsakin, Oluwafemi Olumide Oyetunji   +3 more
doaj   +1 more source

Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical Isolates

Journal of Medical Virology
Lenacapavir (LEN) is a potent, first‐in‐class long‐acting HIV‐1 capsid (CA) inhibitor, approved for treatment of people with multi‐drug resistant HIV in combination with other antiretrovirals.
Sally Demirdjian, Vidula Naik, N. Margot, Brie Falkard, Christian Callebaut   +4 more
semanticscholar   +1 more source

Breaking barriers for key populations in the lenacapavir era

Decoding Infection and Transmission
Despite advances in human immunodeficiency virus (HIV) prevention, key populations including men who have sex with men (MSM), sex workers, transgender individuals, people who inject drugs, and adolescent girls and young women (AGYW) continue to ...
Victor Abiola Adepoju, Abdulrakib Abdulrahim, Safayet Jamil   +2 more
doaj   +1 more source

Lenacapavir for HIV PrEP: Narrative Review of Clinical Trials and Implications for Patient Access

Current Treatment Options in Infectious Diseases
By the end of 2023, approximately 39.9 million people worldwide were living with HIV, including 1.2 million in the United States. Although treatment advancements have improved health outcomes, HIV continues to pose significant challenges, particularly ...
Swarnali Goswami, S. Veeramachaneni, Prajakta P. Masurkar   +2 more
semanticscholar   +1 more source

A theoretical study of the atropodiastereomerism of Lenacapavir

This paper presents a theoretical study of Lenacapavir, a promising drug for HIV prevention, with the dual objective of reproducing experimental results of the R a and predicting the properties of the less stable ...
José Elguero, Ibon Alkorta
core   +1 more source